Psychedelics on Brambles

Psilomethoxin, My Case Report (Addendum #3)

Sun, 03 May 2026 00:00:00 +0000

I recently tried 5-MAPB (5-(2-methylaminopropyl)benzofuran) at 80mg on a single occasion—my first experience with an MDMA-like compound. This gave me a useful point of comparison with psilomethoxin (Pm).

In my judgment, Pm at 0.5–1g most closely resembles 5-MAPB. Below that range, Pm is too subtle; above it, the experience pulls inward too firmly in a way that diverges from the 5-MAPB character.

The comparison confirmed differences I had suspected. 5-MAPB is a stimulant—sleep on the day of administration was a challenge. Pm is not a stimulant; as noted in the original case report, falling asleep at the peak is possible.

Joshua interviewed on the Cannabis Potcast

Sun, 29 Dec 2024 00:00:00 +0000

For more details, check out my cannabis page.

Jennifer Murphey

Sun, 10 Nov 2024 00:00:00 +0000

Jennifer Murphey bares her soul during her talk at Entheogenesis in Austin, TX on April 15, 2023.

Monday, June 24th 2024 at 7pm at Meraki Kava Bar, Jennifer Murphey discusses the War on Drugs and her part in fighting it.

Navigating Psilomethoxin: Josh’s Research & Practical Advice

Wed, 18 Sep 2024 00:00:00 +0000

Episode 7 of The Sacred Synthesis Podcast

Chat about Sacred Synthesis and Psilomethoxin

Thu, 06 Jun 2024 00:00:00 +0000

Comment on Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I

Mon, 18 Dec 2023 00:00:00 +0000

Drug regulation should not be a criminal matter, but addressed by health care providers. I urge the DEA to drop this attempt to schedule more substances.

Personal Liberty: At the heart of the decriminalization movement lies the principle of individual autonomy. Adults should have the right to choose what they put into their own bodies, as long as their actions don’t harm others. Criminalizing personal drug use infringes on this fundamental freedom, treating individuals as criminals for making private choices.

Psilomethoxin, My Case Report (Addendum #2)

Mon, 09 Oct 2023 00:00:00 +0000

Purely based on subjective experience, I estimate the pharmacodynamics as:

pm <- function(x) 7.5*dchisq(4*(x-.5), 6)

The x axis is hours and the y axis is scaled so that 1 = a capsule of dried Pm mushroom powder.

plot(function(x) pm(x), 0,6, xlab="hours",ylab="capsules")

Using this function, you can estimate the effect of multiple capsules taken at different times. For example, suppose you take 2 at 10am, 1 at 10:45am, 1 at 11:15am, and 1 at 11:45am. If you space out 5 capsules like this then the peak is only about 3.5 capsules worth at 1pm:

Psilomethoxin, My Case Report (Addendum #1)

Sun, 03 Sep 2023 00:00:00 +0000

I have had IFS sessions with one client on multiple occasions with a self-administered psycholytic dose of psilomethoxin (Pm). In addition, I have shared Pm with five people Z, M, W, K1, and K2. What surprised me most from this exploration is that Pm seems to have a built-in exit valve. Or from the opposite point of view, the user only experiences the effects of Pm when focused inside. If you focus outside then you can completely miss the effects. For traditional psychedelics, an exit valve is an aspiration.¹ For Pm, it seems already built-in!

Psychedelic use by facilitators

Wed, 03 May 2023 00:00:00 +0000

Abstract: The use of psychedelics in therapy may benefit both the client and the facilitator, and there is a debate about whether facilitators should have personal experience with the substance. While some traditions expect the facilitator to partake in the same dose as the participants, modern medicine expects the facilitator to remain sober. Facilitator sobriety is important to attend to the risks associated with psychedelic use, while communal use of the substance may increase empathy and compassion. Further research is needed to determine the circumstances in which facilitator sobriety or communal use is appropriate.

Psilomethoxin, My Case Report

Thu, 16 Feb 2023 00:00:00 +0000

At the end of 2022, a new psychedelic became available. Psilomethoxin (Pm) offers a subjective experience similar to MDMA, but without MDMA’s stimulant-like effects.

<—>

In 1965, Marc Julia’s group at the Pasteur Institute synthesized psilomethoxin (Pm) from ortho-vanillin extracted from the Mexican vanilla orchid. The molecule was never bioassayed nor preserved as a reference sample, and that is how things stood for decades. The synthesis of Pm is an intricate and time-consuming process, with some chemists claiming that it would take a month. In approximately 2005, Alexander Shulgin published an article on his website Cognitive Liberty wherein he theorized that Pm might be produced by feeding 5-MeO-DMT to Psilocybe mushroom substrates. In late 2021, Ian Benouis discovered the Shulgin article, tried it, and found that it worked. Pm is chemically similar to 5-MeO-DMT, with the mere addition of a 4-hydroxyl group. The psychedelic 5-MeO-DMT is not orally active and is typically vaporized for inhalation. When inhaled, the experience lasts for 10-20 minutes. Pm is thought to be an orally active version of 5-MeO-DMT.¹